Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5%

Cue Biopharma, Inc. (NASDAQ:CUE) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 1,000,000 shares, a decrease of 6.5% from the November 15th total of 1,070,000 shares. Based on an average trading volume of 762,400 shares, the short-interest ratio is currently 1.3 days.

Analysts Set New Price Targets

Separately, Stifel Nicolaus reduced their target price on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, August 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $5.00.

Institutional Trading of Cue Biopharma

A number of hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in Cue Biopharma by 5.1% during the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock worth $221,000 after acquiring an additional 14,104 shares during the last quarter. Geode Capital Management LLC boosted its position in Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after acquiring an additional 16,371 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Cue Biopharma during the second quarter worth approximately $66,000. Good Life Advisors LLC grew its stake in shares of Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after buying an additional 75,000 shares during the period. Finally, Sigma Planning Corp grew its stake in shares of Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after buying an additional 135,295 shares during the period. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Price Performance

Shares of CUE stock traded up $0.08 during trading hours on Monday, hitting $1.02. The company’s stock had a trading volume of 249,644 shares, compared to its average volume of 454,110. The business has a fifty day moving average of $1.33 and a 200-day moving average of $1.06. The stock has a market cap of $64.62 million, a price-to-earnings ratio of -1.16 and a beta of 1.66. Cue Biopharma has a twelve month low of $0.45 and a twelve month high of $3.20. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05.

About Cue Biopharma

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.